Hoffwn ddiolch i Grŵp Strategaeth Feddyginiaethau Cymru (AWMSG) am eu hystyriaeth ofalus o Truvada® i’w ddefnyddio at broffylacsis cyn-gysylltiad i leihau’r perygl o ddal HIV drwy ryw o blith oedolion yn y perygl mwyaf o’i ddal. Grŵp arbenigol, annibynnol yw AWMSG, wedi ei gydnabod a’i achredu. Mae’n rhaid i mi gydnabod eu cyngor bod gormod o ansicrwydd o ran lefelau cost-effeithiolrwydd, sy’n golygu nad ydynt wedi ei argymell i’w ddefnyddio fel rheol yn y GIG yng Nghymru ar hyn o bryd.
I would like to thank the All-Wales Medicines Strategy Group (AWMSG) for their careful consideration of Truvada® for use as pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV amongst adults at high risk. AWMSG are a recognised and accredited independent expert group. I must acknowledge their advice that there are uncertainties around the levels of cost-effectiveness which led them not to recommend it for routine use within the NHS in Wales at this time.